Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT06561347
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06557330
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 36
- Registration Number
- NCT06554600
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- SecuraBio
- Target Recruit Count
- 124
- Registration Number
- NCT06522737
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06496308
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
- Conditions
- Recurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinosarcomaRecurrent Platinum-Resistant Ovarian CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent Female Reproductive System CarcinomaRecurrent Primary Peritoneal CarcinosarcomaRefractory Ovarian Carcinoma
- Interventions
- Biological: Autologous MUC1-activated T-cellsDrug: BendamustineProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT06483048
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 220
- Registration Number
- NCT06477549
- Locations
- 🇷🇺
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT06465446
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇩🇪Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany
🇮🇹Local Institution - 0179, Rozzano, Milano, Italy
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.